IL264144B2 - Antibody 18A2 against CLAUDIN and its use - Google Patents

Antibody 18A2 against CLAUDIN and its use

Info

Publication number
IL264144B2
IL264144B2 IL264144A IL26414419A IL264144B2 IL 264144 B2 IL264144 B2 IL 264144B2 IL 264144 A IL264144 A IL 264144A IL 26414419 A IL26414419 A IL 26414419A IL 264144 B2 IL264144 B2 IL 264144B2
Authority
IL
Israel
Prior art keywords
seq
antibody
variable region
cell
chain variable
Prior art date
Application number
IL264144A
Other languages
English (en)
Hebrew (he)
Other versions
IL264144B1 (en
IL264144A (en
Inventor
Huamao Wang
Peng Wang
Hua Jiang
Linlin Yang
Zhimin Shi
Zonghai Li
Original Assignee
Carsgen Therapeutics Co Ltd
Shanghai Cancer Inst
Cafa Therapeutics Ltd
Crage Medical Co Ltd
Huamao Wang
Peng Wang
Hua Jiang
Linlin Yang
Zhimin Shi
Zonghai Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2017/082024 external-priority patent/WO2017186121A1/zh
Application filed by Carsgen Therapeutics Co Ltd, Shanghai Cancer Inst, Cafa Therapeutics Ltd, Crage Medical Co Ltd, Huamao Wang, Peng Wang, Hua Jiang, Linlin Yang, Zhimin Shi, Zonghai Li filed Critical Carsgen Therapeutics Co Ltd
Publication of IL264144A publication Critical patent/IL264144A/en
Publication of IL264144B1 publication Critical patent/IL264144B1/en
Publication of IL264144B2 publication Critical patent/IL264144B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL264144A 2016-07-08 2017-07-10 Antibody 18A2 against CLAUDIN and its use IL264144B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610536449 2016-07-08
PCT/CN2017/082024 WO2017186121A1 (zh) 2016-04-26 2017-04-26 一种改善免疫应答细胞功能的方法
PCT/CN2017/092381 WO2018006882A1 (zh) 2016-07-08 2017-07-10 抗密蛋白18a2的抗体及其应用

Publications (3)

Publication Number Publication Date
IL264144A IL264144A (en) 2019-02-28
IL264144B1 IL264144B1 (en) 2023-07-01
IL264144B2 true IL264144B2 (en) 2023-11-01

Family

ID=60912336

Family Applications (1)

Application Number Title Priority Date Filing Date
IL264144A IL264144B2 (en) 2016-07-08 2017-07-10 Antibody 18A2 against CLAUDIN and its use

Country Status (13)

Country Link
US (2) US11111295B2 (OSRAM)
EP (1) EP3483182B1 (OSRAM)
JP (1) JP7587921B2 (OSRAM)
KR (1) KR102723896B1 (OSRAM)
CN (1) CN109790222B (OSRAM)
AU (1) AU2017294276B2 (OSRAM)
BR (1) BR112019000327A8 (OSRAM)
CA (1) CA3030257A1 (OSRAM)
CL (1) CL2019000061A1 (OSRAM)
ES (1) ES2979068T3 (OSRAM)
IL (1) IL264144B2 (OSRAM)
SG (1) SG11201900171QA (OSRAM)
WO (1) WO2018006882A1 (OSRAM)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790222B (zh) * 2016-07-08 2022-03-15 克莱格医学有限公司 抗密蛋白18a2的抗体及其应用
EP3747433A4 (en) 2018-02-02 2021-12-22 Cafa Therapeutics Limited CELLULAR IMMUNOTHERAPY ASSOCIATION
MX2020009326A (es) * 2018-03-08 2020-10-08 Phanes Therapeutics Inc Anticuerpos anti-claudina 18.2 y usos de los mismos.
WO2019170147A1 (zh) * 2018-03-09 2019-09-12 科济生物医药（上海）有限公司 用于治疗肿瘤的方法和组合物
BR112020014591A2 (pt) * 2018-03-14 2020-12-01 Beijing Xuanyi Pharmasciences Co., Ltd. anticorpos anticlaudina 18.2
EP3789486A4 (en) * 2018-05-03 2022-03-30 Cafa Therapeutics Limited Immune effector cell and use thereof
KR20210018838A (ko) 2018-05-15 2021-02-18 카르스젠 테라퓨틱스 컴퍼니, 리미티드 유전자 조작된 세포 및 응용
WO2019219089A1 (en) * 2018-05-18 2019-11-21 Bridge Health Bio-Tech Co., Ltd Anti-claudin 18.2 antibodies and uses thereof
CA3107515A1 (en) 2018-07-24 2020-01-30 Carsgen Therapeutics Co., Ltd. Method for tumor treatment with immune effector cells
US12054543B2 (en) * 2018-07-25 2024-08-06 Accurus Biosciences, Inc. CLDN 18.2-specific monoclonal antibodies and methods of use thereof
CN110857322A (zh) * 2018-08-22 2020-03-03 瑞阳(苏州)生物科技有限公司 抗人claudin 18.2单克隆抗体及其应用
US20220119517A1 (en) * 2018-08-27 2022-04-21 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-claudin18.2 antibody and use thereof
CN109206524B (zh) * 2018-09-25 2022-04-05 山东兴瑞生物科技有限公司 抗Claudin18A2嵌合抗原受体、其修饰的T细胞及T细胞制备方法和用途
KR20210072027A (ko) * 2018-09-30 2021-06-16 카파 테라퓨틱스 리미티드 Cldn18의 항체 및 화학요법 약물의 병용 요법
CN113164408B (zh) 2018-12-07 2025-07-22 克莱格医学有限公司 肿瘤联合免疫治疗
KR20210100655A (ko) * 2018-12-07 2021-08-17 제트엘아이피 홀딩 리미티드 항-클라우딘 항체 및 이의 용도
JP7562528B2 (ja) * 2018-12-28 2024-10-07 四川科倫博泰生物医薬股▲フン▼有限公司 抗体及びその用途
EP3902839A4 (en) * 2018-12-28 2022-12-14 Nanjing GenScript Biotech Co., Ltd. 18.2 CLAUDINE BINDING FRACTIONS AND THEIR USES
CN113271953A (zh) 2019-01-07 2021-08-17 科济生物医药（上海）有限公司 细胞免疫治疗的组合
CN111434692B (zh) * 2019-01-15 2021-12-31 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
US11407828B2 (en) 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
CN113490689B (zh) * 2019-02-01 2024-06-04 恺兴生命科技(上海)有限公司 Tcr融合蛋白及表达tcr融合蛋白的细胞
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN120944827A (zh) * 2019-03-27 2025-11-14 宾夕法尼亚大学董事会 Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
KR20210144792A (ko) * 2019-03-29 2021-11-30 페인스 테라퓨틱스 인코포레이티드 인간화된 항-클라우딘 18.2 키메라 항원 수용체 및 그의 용도
CN116063516A (zh) * 2019-04-01 2023-05-05 江苏恒瑞医药股份有限公司 抗Claudin18.2抗体及其应用
CN113748133B (zh) * 2019-04-19 2024-07-02 康诺亚生物医药科技（成都）有限公司 肿瘤治疗剂及其应用
WO2020228806A1 (zh) 2019-05-16 2020-11-19 齐鲁制药有限公司 针对密蛋白18a2的抗体及其应用
CN111978402B (zh) * 2019-05-24 2022-06-28 三优生物医药(上海)有限公司 新型cldn18.2结合分子
CA3141504A1 (en) * 2019-05-24 2020-12-03 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
US12312402B2 (en) 2019-05-30 2025-05-27 Shandong Boan Biotechnology Co., Ltd. Antibody or chimeric antigen receptor which targets Claudin 18.2
IL289663B2 (en) * 2019-07-17 2024-11-01 Univ California Claudin18 antibodies and methods of treating cancer
EP3853257A4 (en) * 2019-08-12 2022-06-29 I-Mab Biopharma US Limited Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof
CN112574307B (zh) 2019-09-29 2023-11-28 迈威(上海)生物科技股份有限公司 抗人Claudin18.2抗体及其应用
WO2021088927A1 (en) * 2019-11-05 2021-05-14 Lanova Medicines Limited Company Antibody-drug conjugates targeting claudin 18.2
WO2021104511A1 (zh) * 2019-11-29 2021-06-03 苏州诺沃泰医药科技有限公司 Cart细胞在制备治疗癌症的药物中的应用
AU2020398045A1 (en) 2019-12-06 2022-06-09 Sotio Biotech A.S. Humanized CLDN18.2 antibodies
AU2020410998A1 (en) 2019-12-23 2022-06-16 Sotio Biotech A.S. Tumor-specific Claudin 18.2 antibodies
CN113272332B (zh) * 2020-01-03 2022-11-18 上海恺兴诊断技术有限公司 抗Claudin18.2的抗体及其应用
US12060434B2 (en) * 2020-02-25 2024-08-13 Gensun Biopharma Inc. Trispecific T cell engagers
JP7522482B2 (ja) * 2020-02-10 2024-07-25 上海詩健生物科技有限公司 クローディン１８．２の抗体及びその使用
WO2021228141A1 (zh) * 2020-05-15 2021-11-18 四川科伦博泰生物医药股份有限公司 抗体药物缀合物及其制备方法和用途
CA3178855A1 (en) * 2020-06-19 2021-12-23 Innovent Biologics (Suzhou) Co., Ltd. Anti-claudin18.2 antibody and use thereof
CN111961135B (zh) * 2020-07-13 2022-08-16 北京亦庄国际蛋白药物技术有限公司 一种用于预防或治疗癌症的抗体
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
CN114222761B (zh) * 2020-07-14 2024-02-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
US20230310600A1 (en) 2020-08-07 2023-10-05 Crage Medical Co., Limited Engineered cells and method for engineering cells
US20240034784A1 (en) * 2020-09-30 2024-02-01 Nanjing GenScript Biotech Co., Ltd. Antibodies targeting human claudin 18.2 and uses thereof
WO2022122709A1 (en) * 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス，インコーポレイテッド プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
WO2022136642A1 (en) 2020-12-23 2022-06-30 Sotio Biotech A.S. Tumor-specific claudin 18.2 antibody-drug conjugates
US20220251505A1 (en) 2021-01-29 2022-08-11 Allogene Therapeutics, Inc. KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
US20240181055A1 (en) 2021-04-08 2024-06-06 Crage Medical Co., Limited Cellular immunotherapy use
WO2022218375A1 (zh) * 2021-04-15 2022-10-20 克莱格医学有限公司 嵌合t细胞受体及其应用
EP4365193A4 (en) 2021-06-29 2024-12-25 Carsgen Therapeutics Co., Ltd. Chimeric polypeptide for regulating cell physiological activity
CN113788894B (zh) * 2021-09-03 2022-08-05 深圳市先康达生命科学有限公司 靶向人Claudin18.2蛋白的单克隆抗体及其应用
CN118139888A (zh) * 2021-11-05 2024-06-04 正大天晴药业集团股份有限公司 抗cldn18.2抗体及其用途
WO2023213280A1 (zh) * 2022-05-06 2023-11-09 上海先博生物科技有限公司 靶向cldn18.2的嵌合抗原t细胞受体及其应用
WO2024022495A1 (en) * 2022-07-28 2024-02-01 Concept To Medicine Biotech Co., Ltd. Anti-MerTK ANTIBODIES AND USES THEREOF
JP2025525779A (ja) 2022-07-29 2025-08-07 アロジーン セラピューティクス，インコーポレイテッド 免疫細胞の認識を低減させるために遺伝子発現が低下した、操作された細胞
CN118873678A (zh) 2023-01-18 2024-11-01 泰励生物科技（上海）有限公司 抗体偶联药物及其用途
WO2025026347A1 (en) * 2023-07-31 2025-02-06 Nanjing Legend Biotech Co., Ltd. Chimeric cytokine receptors and methods of use thereof
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
CN117430708B (zh) * 2023-12-21 2024-04-09 苏州近岸蛋白质科技股份有限公司 一种抗Claudin18.2抗体
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN120005046B (zh) * 2025-04-18 2025-09-02 深锐(天津)生物医学有限公司 双靶点嵌合抗原受体联合pd-1与il-21融合蛋白

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101312989A (zh) * 2005-11-24 2008-11-26 加尼梅德药物公司 用于治疗癌症的针对密蛋白-18的单克隆抗体
WO2016008405A1 (zh) * 2014-07-17 2016-01-21 科济生物医药（上海）有限公司 靶向cld18a2的免疫效应细胞及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
PE20181302A1 (es) 2015-12-04 2018-08-09 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-claudina y sus metodos de uso
CN108884459B (zh) * 2016-04-26 2024-04-02 科济生物医药（上海）有限公司 一种改善免疫应答细胞功能的方法
CN109790222B (zh) * 2016-07-08 2022-03-15 克莱格医学有限公司 抗密蛋白18a2的抗体及其应用
WO2019170147A1 (zh) * 2018-03-09 2019-09-12 科济生物医药（上海）有限公司 用于治疗肿瘤的方法和组合物
KR20210072027A (ko) * 2018-09-30 2021-06-16 카파 테라퓨틱스 리미티드 Cldn18의 항체 및 화학요법 약물의 병용 요법
CN113271953A (zh) * 2019-01-07 2021-08-17 科济生物医药（上海）有限公司 细胞免疫治疗的组合
WO2022033483A1 (zh) * 2020-08-10 2022-02-17 佧珐药业有限公司 多功能的免疫效应细胞及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101312989A (zh) * 2005-11-24 2008-11-26 加尼梅德药物公司 用于治疗癌症的针对密蛋白-18的单克隆抗体
WO2016008405A1 (zh) * 2014-07-17 2016-01-21 科济生物医药（上海）有限公司 靶向cld18a2的免疫效应细胞及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAHIN UGUR ET AL,, CLAUDIN-18 SPLICE VARIANT 2 IS A PAN-CANCER TARGET SUITABLE FOR THERAPEUTIC ANTIBODY DEVELOPMENT, 1 December 2008 (2008-12-01) *

Also Published As

Publication number Publication date
KR20190038564A (ko) 2019-04-08
EP3483182A4 (en) 2020-07-29
EP3483182A1 (en) 2019-05-15
RU2019101430A3 (OSRAM) 2021-05-17
BR112019000327A2 (pt) 2019-08-13
AU2017294276A1 (en) 2019-02-28
JP7587921B2 (ja) 2024-11-21
IL264144B1 (en) 2023-07-01
WO2018006882A1 (zh) 2018-01-11
NZ750420A (en) 2025-06-27
CA3030257A1 (en) 2018-01-11
US20190233511A1 (en) 2019-08-01
US11111295B2 (en) 2021-09-07
JP2019531084A (ja) 2019-10-31
KR102723896B1 (ko) 2024-11-01
IL264144A (en) 2019-02-28
EP3483182B1 (en) 2024-05-08
CN109790222B (zh) 2022-03-15
US20220185880A1 (en) 2022-06-16
BR112019000327A8 (pt) 2022-10-18
SG11201900171QA (en) 2019-02-27
RU2019101430A (ru) 2020-08-10
CN109790222A (zh) 2019-05-21
CL2019000061A1 (es) 2019-05-03
AU2017294276B2 (en) 2024-08-01
ES2979068T3 (es) 2024-09-24

Similar Documents

Publication Publication Date Title
IL264144B2 (en) Antibody 18A2 against CLAUDIN and its use
CN108610420B (zh) 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
CN112639102B (zh) 抗间皮素嵌合抗原受体(car)构建体及其用途
AU2018241624B2 (en) Improved antigen binding receptors
CA3032054A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
FI4324851T3 (fi) BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä
JP7064663B2 (ja) Ｉｌ－１３ｒａ２を標的とする抗体及びその応用
CA3030837A1 (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CN113784980B (zh) 人源化抗Claudin18.2嵌合抗原受体及其用途
CN104592392B (zh) 一种双特异性抗体EpCAM×CD3的构建及应用
US20240092856A1 (en) Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
US20220072103A1 (en) Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
US20240262913A1 (en) Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
EP4613781A1 (en) Immune rejection-resistant engineered cell
JP2026500705A (ja) Ｒｏｒ１を標的とする抗原結合タンパク質
US20240158500A1 (en) CD160 Binding Domain
US20240174768A1 (en) Bispecific antibodies enhancing cell mediated immune responses
NZ750420B2 (en) Antibody for anti-claudin 18a2 and use thereof
JP2025157279A (ja) Ｐｄ－１標的化ｉｌ－２変異体免疫サイトカインとヒトｐｄ－ｌ１に対する抗体との併用療法
TW202444751A (zh) 重組Ｆｃ域—ＩＬ２變異體多肽及與膜錨定抗原結合多肽的組合療法
KR20220033140A (ko) Pd-1-표적화된 il-2 변이체 면역사이토카인 및 인간 pd-l1에 대한 항체의 병용 요법
CA3092371A1 (en) Combination therapy of pd-1-targeted il-2 variant immunocytokines and antibodies against human pd-l1
HK40008908A (en) Anti-cd19 humanized antibody and immune effector cell targeting cd19